Use of naproxen or celecoxib does not prevent Alzheimer's disease (AD), at least within the early years after treatment initiation, according to a randomized, placebo-controlled, multicenter study.
Use of naproxen or celecoxib does not prevent Alzheimer's disease (AD), at least within the early years after treatment initiation, according to a randomized, placebo-controlled, multicenter study published in the journal Neurology.
The purpose of the AD Anti-inflammatory Prevention Trial (ADAPT) was to investigate whether AD could be prevented or delayed with the use of celecoxib or naproxen. Existing epidemiologic evidence indicates that use of nonsteroidal anti-inflammatory drugs (NSAIDs) for ≥2 years is associated with a reduced incidence of AD. Although the causes of AD are not well understood, neuropathologic evidence suggests the involvement of inflammatory processes.
The authors stated that primary analyses demonstrated an inconclusive trend towards increased AD incidence with either NSAID treatment. In secondary analyses (excluding the 7 patients with dementia at baseline), the HRs for AD development were 1.52 for celecoxib (P=.24) and 1.46 for naproxen (P=.30) compared with placebo.
The authors stated that because previous observational data suggest that NSAIDs may have protective effects for individuals whose onset of AD would be farther in the future than that measured in ADAPT, continued follow-up of the ADAPT cohort is warranted. The current data suggest that celecoxib and naproxen are not indicated for AD prevention but, according to the authors, the data are too limited to be considered evidence that those at risk for AD should avoid these or other NSAIDs.
SOURCE
Lyketsos CG, Breitner JCS, Green RC, et al; for the ADAPT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology. 2007;68:1800–1808.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
ICER Gives Cell Therapy for Post-Transplant Complications High Rating
Published: October 31st 2024 | Updated: October 31st 2024ICER has given tabelecleucel a rating of A, indicating the T cell therapy for Epstein-Barr virus related post-transplant lymphoproliferative disease has a high certainty of substantial net health benefit and would be cost-effective if priced between $143,900 and $273,700.
Read More